- Home
- NVNI vs CUE Comparison
NVNI vs CUE Comparison
Compare NVNI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- CUE
- Stock Information
- Founded
- NVNI 2019
- CUE 2014
- Country
- NVNI Brazil
- CUE United States
- Employees
- NVNI N/A
- CUE N/A
- Industry
- NVNI
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- CUE Health Care
- Exchange
- NVNI Nasdaq
- CUE Nasdaq
- Market Cap
- NVNI 57.2M
- CUE 61.1M
- IPO Year
- NVNI N/A
- CUE 2018
- Fundamental
- Price
- NVNI $4.13
- CUE $0.80
- Analyst Decision
- NVNI
- CUE Strong Buy
- Analyst Count
- NVNI 0
- CUE 2
- Target Price
- NVNI N/A
- CUE $3.00
- AVG Volume (30 Days)
- NVNI 1.3M
- CUE 283.3K
- Earning Date
- NVNI 09-30-2025
- CUE 11-13-2025
- Dividend Yield
- NVNI N/A
- CUE N/A
- EPS Growth
- NVNI N/A
- CUE N/A
- EPS
- NVNI N/A
- CUE N/A
- Revenue
- NVNI $31,250,627.00
- CUE $8,286,000.00
- Revenue This Year
- NVNI $12.05
- CUE N/A
- Revenue Next Year
- NVNI $15.02
- CUE N/A
- P/E Ratio
- NVNI N/A
- CUE N/A
- Revenue Growth
- NVNI 1491.58
- CUE N/A
- 52 Week Low
- NVNI $1.44
- CUE $0.54
- 52 Week High
- NVNI $121.90
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- NVNI 71.42
- CUE 53.24
- Support Level
- NVNI $2.96
- CUE $0.78
- Resistance Level
- NVNI $4.94
- CUE $0.96
- Average True Range (ATR)
- NVNI 0.51
- CUE 0.06
- MACD
- NVNI 0.21
- CUE 0.01
- Stochastic Oscillator
- NVNI 83.44
- CUE 39.12
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.